Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.
Intracellular neurofibrillary tangles (NFTs) composed of tau protein are a neuropathological hallmark of several neurodegenerative diseases, the most common of which is Alzheimer's disease (AD). For some time NFTs were considered the primary cause of synaptic dysfunction and neuronal death, however, more recent evidence suggests that soluble aggregates of tau are key drivers of disease. Here we investigated the effect of different tau species on synaptic plasticity in the male rat hippocampus in vivo Intracerebroventricular injection of soluble aggregates formed from either wild-type or P301S human recombinant tau potently inhibited hippocampal long-term potentiation (LTP) at CA3-to-CA1 synapses. In contrast, tau monomers and fibrils appeared inactive. Neither baseline synaptic transmission, paired-pulse facilitation nor burst response during high-frequency conditioning stimulation was affected by the soluble tau aggregates. Similarly, certain AD brain soluble extracts inhibited LTP in a tau-dependent manner that was abrogated by either immunodepletion with, or coinjection of, a mid-region anti-tau monoclonal antibody (mAb), Tau5. Importantly, this tau-mediated block of LTP was prevented by administration of mAbs selective for the prion protein (PrP). Specifically, mAbs to both the mid-region (6D11) and N-terminus (MI-0131) of PrP prevented inhibition of LTP by both recombinant and brain-derived tau. These findings indicate that PrP is a mediator of tau-induced synaptic dysfunction.SIGNIFICANCE STATEMENT Here we report that certain soluble forms of tau selectively disrupt synaptic plasticity in the live rat hippocampus. Further, we show that monoclonal antibodies to cellular prion protein abrogate the impairment of long-term potentiation caused both by recombinant and Alzheimer's disease brain-derived soluble tau. These findings support a critical role for cellular prion protein in the deleterious synaptic actions of extracellular soluble tau in tauopathies, including Alzheimer's disease. Thus, approaches targeting cellular prion protein, or downstream pathways, might provide an effective strategy for developing therapeutics.
['Ondrejcak|Tomas|T|', 'Klyubin|Igor|I|', 'Corbett|Grant T|GT|0000-0003-3606-9686', 'Fraser|Graham|G|', 'Hong|Wei|W|', 'Mably|Alexandra J|AJ|', 'Gardener|Matthew|M|', 'Hammersley|Jayne|J|', 'Perkinton|Michael S|MS|', 'Billinton|Andrew|A|', 'Walsh|Dominic M|DM|0000-0002-0718-6261', 'Rowan|Michael J|MJ|']
D000368:Aged D000369:Aged, 80 and over D000544:Alzheimer Disease D020533:Angiogenesis Inhibitors D000818:Animals D005260:Female D006624:Hippocampus D006801:Humans D008297:Male D009473:Neuronal Plasticity D018621:PrPC Proteins D000072002:Prion Proteins D051381:Rats D016875:tau Proteins
prion protein synaptic plasticity Alzheimer's disease glutamate microtubule-associated protein tau